The Complex Treatment with Mellozan Immunomodulator of Patients with Multidrug-Resistant Tuberculosis

摘要

Development of resistance to antitubercular drugs significantly complicates the anti-tuberculosis treatment.63 patients with active pulmonary multidrug-resistant tuberculosis were supervised. All patients followed the treatment according to the DOTS Plus strategy scheme in association with Mellozan immunomodulator administered daily by 1 or 2 ml intramuscular. Duration of treatment-10 days.Out of 63 patients with multidrug-resistant tuberculosis included in the study, in 61 an improvement of the clinical condition, as well as disappearance of intoxication symptoms were noticed after the administration of Mellozan . The effectiveness of the causal treatment also increased. The regress of the asthenic syndrome and the improvement of the life quality were recorded. The obtained data can underlie a special analysis aimed at optimizing the treatment of patients with tuberculosis with the use of Mellozan, establishing the duration of treatment and the number of treatments for different categories of patients.